Clinical Trials Browser

Phase 2 × Withdrawn × zalutumumab × Clear all

NCT01449357 2011-10-10

Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung